CellSource Co., Ltd. (4880) AI Stock Analysis

• Market Cap: ¥7.71B
• Dividend Yield: 1.29%
• Average Volume (3M): 77.65K
• Price to Earnings (P/E): 750.9
• Beta (1Y): 0.73
• Revenue Growth: -14.78%
• EPS Growth: -95.53%
• Country: JP
• Employees: 151
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -3.81
• Shares Outstanding: 19,819,962
• 10 Day Avg. Volume: 73,510
• 30 Day Avg. Volume: 77,646
• PEG Ratio: -9.83
• Price to Book (P/B): 1.66
• Price to Sales (P/S): 2.70
• P/FCF Ratio: 34.51
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 51 Neutral
• Price Target: ¥388.00 ▼(-2.76% Downside)

CellSource Co., Ltd. faces significant challenges with profitability and market sentiment. Despite strong revenue growth and a solid balance sheet, high valuation and bearish technical indicators weigh heavily on the stock's outlook.

Positive Factors

Revenue Growth

Strong revenue growth indicates successful market penetration and product adoption, supporting long-term business expansion and sustainability.

Balance Sheet Health

A robust balance sheet with low leverage enhances financial stability, providing flexibility for strategic investments and resilience against economic downturns.

Cash Generation Ability

Strong cash generation relative to net income ensures liquidity for operations and investments, supporting sustainable growth and financial health.

Negative Factors

Profit Margin Decline

A sharp decline in profit margins suggests increased operational costs or inefficiencies, potentially impacting long-term profitability and competitiveness.

Declining Return on Equity

A significant drop in return on equity indicates challenges in effectively utilizing shareholder capital, which could hinder future growth and investor confidence.

Free Cash Flow Challenges

Negative free cash flow growth limits the company's ability to fund operations and investments internally, potentially increasing reliance on external financing.

CellSource Co., Ltd. Business Overview & Revenue Model

Company Description

CellSource Co., Ltd. (4880) is a biotechnology company focused on the development and commercialization of innovative cellular therapies. The company operates primarily in the healthcare sector, specializing in stem cell research and regenerative medicine. CellSource's core products include advanced cellular treatments for various diseases and conditions, leveraging proprietary technology to enhance the efficacy and safety of therapies. The firm aims to transform patient care through its cutting-edge solutions that address unmet medical needs.

How the Company Makes Money

CellSource Co., Ltd. generates revenue primarily through the sale of its cellular therapy products and services, which are marketed to hospitals, clinics, and research institutions. The company's revenue model includes direct sales of its therapies as well as partnerships with pharmaceutical firms for co-development and licensing agreements. Additionally, CellSource may earn income through grants and funding for research and development projects in collaboration with academic institutions and government bodies. Significant partnerships with key players in the biotechnology and pharmaceutical industries further bolster its revenue streams, enabling shared resources and expanded market access.

CellSource Co., Ltd. Financial Statement Overview

Summary

CellSource Co., Ltd. shows strong revenue growth but struggles with profitability and cash flow. The balance sheet is robust with low leverage, yet declining return on equity and profit margins indicate operational inefficiencies.

Income Statement

CellSource Co., Ltd. has shown a mixed performance in its income statement. The company experienced a significant revenue growth of 26.49% in the latest year, which is a positive indicator. However, the net profit margin has decreased substantially from 20.47% in 2023 to just 0.29% in 2025, indicating a sharp decline in profitability. The gross profit margin remains relatively stable, but the EBIT and EBITDA margins have also decreased, suggesting increased operational costs or other financial pressures.

Balance Sheet

The balance sheet of CellSource Co., Ltd. reflects a strong equity position with a low debt-to-equity ratio of 0.009, indicating minimal leverage and financial risk. The equity ratio is also healthy, showing that the company is primarily financed through equity. However, the return on equity has significantly decreased from 14.88% in 2023 to 0.18% in 2025, suggesting declining efficiency in generating returns from shareholders' equity.

Cash Flow

The cash flow statement shows a concerning trend with a significant decline in free cash flow growth, which was negative in recent years. The operating cash flow to net income ratio is strong, indicating good cash generation relative to net income. However, the free cash flow to net income ratio has decreased, reflecting challenges in converting income into free cash flow.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	2.82B	3.71B	4.36B	4.51B	4.27B	2.92B
Gross Profit	1.60B	2.09B	2.42B	3.18B	3.06B	2.07B
EBITDA	283.02M	315.48M	449.53M	1.31B	1.64B	1.06B
Net Income	86.28M	10.66M	237.94M	923.14M	1.02B	651.40M
Balance Sheet
Total Assets	7.31B	7.02B	7.07B	6.88B	4.60B	3.37B
Cash, Cash Equivalents and Short-Term Investments	4.63B	4.71B	4.32B	4.78B	3.12B	2.41B
Total Debt	241.08M	56.72M	77.29M	97.54M	0.00	1.10M
Total Liabilities	1.22B	1.01B	1.04B	677.74M	814.15M	645.00M
Stockholders Equity	6.09B	6.02B	6.04B	6.20B	3.79B	2.72B
Cash Flow
Free Cash Flow	0.00	289.90M	52.04M	487.69M	748.44M	836.74M
Operating Cash Flow	0.00	333.10M	591.72M	846.69M	847.60M	898.19M
Investing Cash Flow	0.00	-3.29M	-614.96M	-624.08M	-169.39M	-256.12M
Financing Cash Flow	0.00	61.07M	-437.24M	1.45B	14.42M	9.35M

CellSource Co., Ltd. Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 399.00
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Positive
• STOCH: Positive

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:4880, the sentiment is Negative. The current price of 399 is below the 20-day moving average (MA) of 456.80, below the 50-day MA of 488.68, and below the 200-day MA of 620.10, indicating a bearish trend. The MACD of -30.38 indicates Positive momentum. The RSI at 28.97 is Positive, neither overbought nor oversold. The STOCH value of 10.04 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:4880.

CellSource Co., Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
7096	56 Neutral	¥7.76B	38.95	―	―	2.99%	-52.75%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
4880	51 Neutral	¥7.71B	750.93	―	1.29%	-14.78%	-95.53%
4978	49 Neutral	¥13.27B	-47.59	―	―	1.24%	-33.41%
4599	47 Neutral	¥15.80B	-8.75	―	―	―	11.34%
4888	45 Neutral	¥7.05B	-40.45	―	―	248.15%	76.92%
7776	43 Neutral	¥8.15B	-7.98	―	―	-42.49%	-2.37%

CellSource Co., Ltd. Corporate Events

CellSource Stock Gains Loan Margin Trading Status

CellSource Co., Ltd. has announced that its stock has been newly selected as a Loan Margin Trading Issue on the Japan Securities Finance Co., Ltd., effective October 14, 2025. This selection is expected to enhance the liquidity and supply-demand balance of the company’s stock, promoting active trading and fair pricing.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports September 2025 KPI Results

CellSource Co., Ltd. reported its September 2025 KPI results for contract processing services, noting a stable daily average number of orders at 51.2. The company saw a significant shift in order distribution, with a decrease in self-funded orthopedics orders and an increase in hybrid orthopedics. Efforts are being made to address the decline in self-funded orders through strategic reviews and support services, while initiatives for hybrid orthopedics continue to target key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Reports Nine-Month Financial Results and Positive Full-Year Outlook

CellSource Co., Ltd. reported its consolidated financial results for the nine months ending July 31, 2025, showing net sales of ¥2,818 million and a profit attributable to owners of ¥86 million. The company has shifted to consolidated accounting, making year-on-year comparisons unavailable, but it forecasts full-year net sales of ¥3,774 million and a profit of ¥112 million, indicating a positive outlook for the fiscal year.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Revises Financial Forecasts Amid Contract Changes

CellSource Co., Ltd. has revised its financial forecast for the fiscal year ending October 31, 2025, due to lower-than-expected net sales and profit. The revision is attributed to changes in contract terms for medical institution support services and slower-than-anticipated results from measures to increase orders for contract processing services. The company expects flat sales in contract processing services for self-funded medical institutions and anticipates increased orders from hybrid-type institutions in the fourth quarter.

The most recent analyst rating on (JP:4880) stock is a Hold with a Yen742.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.

CellSource Co., Ltd. Reports Decline in July 2025 Contract Processing Orders

CellSource Co., Ltd. reported a decrease in its July 2025 contract processing orders, with a significant drop in blood-derived product orders for hybrid orthopedics. Despite the decline, the company remains committed to strengthening its organizational structure and maintaining planned order volumes, while continuing initiatives with key medical institutions.

The most recent analyst rating on (JP:4880) stock is a Buy with a Yen1600.00 price target. To see the full list of analyst forecasts on CellSource Co., Ltd. stock, see the JP:4880 Stock Forecast page.